These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34466656)

  • 41. TLR9 and STING agonists cooperatively boost the immune response to SARS-CoV-2 RBD vaccine through an increased germinal center B cell response and reshaped T helper responses.
    Yang JX; Tseng JC; Tien CF; Lee CY; Liu YL; Lin JJ; Tsai PJ; Liao HC; Liu SJ; Su YW; Hsu LC; Chen JK; Huang MH; Yu GY; Chuang TH
    Int J Biol Sci; 2023; 19(9):2897-2913. PubMed ID: 37324951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection.
    Du L; Zhao G; Lin Y; Chan C; He Y; Jiang S; Wu C; Jin DY; Yuen KY; Zhou Y; Zheng BJ
    Vaccine; 2008 Mar; 26(13):1644-51. PubMed ID: 18289745
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan.
    He Y; Yu W; Shen L; Yan W; Xiao L; Qi J; Hu T
    Int J Biol Macromol; 2022 Dec; 222(Pt A):661-670. PubMed ID: 36152702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human Fc-Conjugated Receptor Binding Domain-Based Recombinant Subunit Vaccines with Short Linker Induce Potent Neutralizing Antibodies against Multiple SARS-CoV-2 Variants.
    Chen L; Qi X; Liang D; Li G; Peng X; Li X; Ke B; Zheng H; Liu Z; Ke C; Liao G; Liu L; Feng Q
    Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146579
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
    Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
    mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.
    Steinbuck MP; Seenappa LM; Jakubowski A; McNeil LK; Haqq CM; DeMuth PC
    Sci Adv; 2021 Feb; 7(6):. PubMed ID: 33547083
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Two formulations of coronavirus disease-19 recombinant subunit vaccine candidate made up of S1 fragment protein P1, S2 fragment protein P2, and nucleocapsid protein elicit strong immunogenicity in mice.
    Özcengiz E; Keser D; Özcengiz G; Çelik G; Özkul A; İnçeh FN
    Immun Inflamm Dis; 2022 Dec; 10(12):e748. PubMed ID: 36444622
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.
    McCafferty S; Haque AKMA; Vandierendonck A; Weidensee B; Plovyt M; Stuchlíková M; François N; Valembois S; Heyndrickx L; Michiels J; Ariën KK; Vandekerckhove L; Abdelnabi R; Foo CS; Neyts J; Sahu I; Sanders NN
    Mol Ther; 2022 Sep; 30(9):2968-2983. PubMed ID: 35450821
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells.
    Phetsouphanh C; Khoo WH; Jackson K; Klemm V; Howe A; Aggarwal A; Akerman A; Milogiannakis V; Stella AO; Rouet R; Schofield P; Faulks ML; Law H; Danwilai T; Starr M; Munier CML; Christ D; Singh M; Croucher PI; Brilot-Turville F; Turville S; Phan TG; Dore GJ; Darley D; Cunningham P; Matthews GV; Kelleher AD; Zaunders JJ
    Front Immunol; 2022; 13():1032911. PubMed ID: 36544780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
    Jeong H; Choi YM; Seo H; Kim BJ
    Front Immunol; 2021; 12():637654. PubMed ID: 33732258
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies.
    Rouhani SJ; Yu J; Olson D; Zha Y; Pezeshk A; Cabanov A; Pyzer AR; Trujillo J; Derman BA; O'Donnell P; Jakubowiak A; Kindler HL; Bestvina C; Gajewski TF
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35732350
    [TBL] [Abstract][Full Text] [Related]  

  • 53. COVID-19 vaccine BNT162b1 elicits human antibody and T
    Sahin U; Muik A; Derhovanessian E; Vogler I; Kranz LM; Vormehr M; Baum A; Pascal K; Quandt J; Maurus D; Brachtendorf S; Lörks V; Sikorski J; Hilker R; Becker D; Eller AK; Grützner J; Boesler C; Rosenbaum C; Kühnle MC; Luxemburger U; Kemmer-Brück A; Langer D; Bexon M; Bolte S; Karikó K; Palanche T; Fischer B; Schultz A; Shi PY; Fontes-Garfias C; Perez JL; Swanson KA; Loschko J; Scully IL; Cutler M; Kalina W; Kyratsous CA; Cooper D; Dormitzer PR; Jansen KU; Türeci Ö
    Nature; 2020 Oct; 586(7830):594-599. PubMed ID: 32998157
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pam2CSK4-adjuvanted SARS-CoV-2 RBD nanoparticle vaccine induces robust humoral and cellular immune responses.
    Qiao Y; Zhan Y; Zhang Y; Deng J; Chen A; Liu B; Zhang Y; Pan T; Zhang W; Zhang H; He X
    Front Immunol; 2022; 13():992062. PubMed ID: 36569949
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immune responses against SARS-CoV-2.
    Laotee S; Duangkaew M; Jivapetthai A; Tharakhet K; Kaewpang P; Prompetchara E; Phumiamorn S; Sapsutthipas S; Trisiriwanich S; Somsaard T; Roytrakul S; Duangkhae P; Ongpipattanakul B; Limpikirati P; Pornputtapong N; Arunmanee W
    PLoS One; 2023; 18(7):e0288486. PubMed ID: 37450510
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine.
    Atalis A; Keenum MC; Pandey B; Beach A; Pradhan P; Vantucci C; Jain R; Hosten J; Smith C; Kramer L; Jimenez A; Ochoa MA; Frey D; Roy K
    bioRxiv; 2022 Feb; ():. PubMed ID: 35132413
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines.
    Dickey TH; Ma R; Orr-Gonzalez S; Ouahes T; Patel P; McAleese H; Butler B; Eudy E; Eaton B; Murphy M; Kwan JL; Salinas ND; Holbrook MR; Lambert LE; Tolia NH
    Cell Rep; 2023 Mar; 42(3):112266. PubMed ID: 36943870
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates.
    Seenappa LM; Jakubowski A; Steinbuck MP; Palmer E; Haqq CM; Carter C; Fontenot J; Villinger F; McNeil LK; DeMuth PC
    NPJ Vaccines; 2022 Oct; 7(1):128. PubMed ID: 36307453
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A COVID-19 vaccine candidate based on SARS-CoV-2 spike protein and immune-stimulating complexes.
    Villarraza J; Fuselli A; Gugliotta A; Garay E; Rodríguez MC; Fontana D; Antuña S; Gastaldi V; Battagliotti JM; Tardivo MB; Alvarez D; Castro E; Cassataro J; Ceaglio N; Prieto C
    Appl Microbiol Biotechnol; 2023 Jun; 107(11):3429-3441. PubMed ID: 37093307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.